: 21221915  [PubMed]865. J Heart Lung Transplant. 2011 Feb;30(2):115-23. doi:10.1016/j.healun.2010.12.001.Third INTERMACS Annual Report: the evolution of destination therapy in the UnitedStates.Kirklin JK(1), Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, Ulisney KL, Baldwin JT, Young JB.Author information: (1)Cardiovascular Division, University of Alabama at Birmingham, Alabama 35294,USA. jkirklin@uab.eduThe third annual report of the Interagency Registry for Mechanically AssistedCirculatory Support (INTERMACS) provides documentation of the current landscapeof durable mechanical circulatory support in the United States. With nearly 3,000patients entered into the database, the transition to continuous-flow pumptechnology is evident and dramatic. This report focuses on the rapidly expanding experience with mechanical circulatory support as destination therapy. Thecurrent 1-year survival of 75% with continuous-flow destination therapy provides a benchmark for the evolving application of this therapy.Copyright Â© 2011 International Society for Heart and Lung Transplantation.Published by Elsevier Inc. All rights reserved.